Claudia Crippa

4.9k total citations
50 papers, 981 citations indexed

About

Claudia Crippa is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Claudia Crippa has authored 50 papers receiving a total of 981 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 27 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in Claudia Crippa's work include Multiple Myeloma Research and Treatments (40 papers), Cancer Treatment and Pharmacology (22 papers) and Protein Degradation and Inhibitors (9 papers). Claudia Crippa is often cited by papers focused on Multiple Myeloma Research and Treatments (40 papers), Cancer Treatment and Pharmacology (22 papers) and Protein Degradation and Inhibitors (9 papers). Claudia Crippa collaborates with scholars based in Italy, Netherlands and Finland. Claudia Crippa's co-authors include Mario Boccadoro, Paolo Corradini, Pellegrino Musto, Antonio Palumbo, Francesca Gay, Mónica Galli, Nicola Giuliani, Norbert Pescosta, Sara Bringhen and Tommasina Guglielmelli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Claudia Crippa

45 papers receiving 962 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claudia Crippa Italy	13	818	735	516	76	43	50	981
Jeff Haessler United States	11	861 1.1×	666 0.9×	521 1.0×	98 1.3×	68 1.6×	16	1.0k
Tommasina Guglielmelli Italy	13	710 0.9×	589 0.8×	441 0.9×	124 1.6×	78 1.8×	31	879
Kelly Godby United States	11	695 0.8×	501 0.7×	435 0.8×	99 1.3×	44 1.0×	52	789
Dan Spoon United States	9	1.3k 1.6×	854 1.2×	671 1.3×	171 2.3×	56 1.3×	11	1.4k
Shivlal Pandey United States	4	913 1.1×	634 0.9×	560 1.1×	130 1.7×	66 1.5×	6	1.0k
Mariella Grasso Italy	11	413 0.5×	330 0.4×	249 0.5×	79 1.0×	51 1.2×	29	539
Grigoriy Rekhtman Ukraine	4	538 0.7×	445 0.6×	371 0.7×	165 2.2×	114 2.7×	5	744
MQ Lacy United States	11	408 0.5×	347 0.5×	229 0.4×	81 1.1×	25 0.6×	11	517
S Kulkarni United Kingdom	18	692 0.8×	256 0.3×	334 0.6×	104 1.4×	36 0.8×	32	810
Laxmi Narayana Buddharaju United States	5	269 0.3×	272 0.4×	191 0.4×	92 1.2×	32 0.7×	10	530

Countries citing papers authored by Claudia Crippa

Since Specialization

Citations

This map shows the geographic impact of Claudia Crippa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Crippa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Crippa more than expected).

Fields of papers citing papers by Claudia Crippa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudia Crippa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Crippa. The network helps show where Claudia Crippa may publish in the future.

Co-authorship network of co-authors of Claudia Crippa

This figure shows the co-authorship network connecting the top 25 collaborators of Claudia Crippa. A scholar is included among the top collaborators of Claudia Crippa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia Crippa. Claudia Crippa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Belotti, Angelo, Barbara Frittoli, Rossella Ribolla, et al.. (2025). Early identification of functional high-risk multiple myeloma patients after transplant: the predictive power of fat fraction and Response Assessment Category score in diffusion-weighted whole-body magnetic resonance imaging. Haematologica. 110(9). 2151–2159.

Mendes, Gonçalo, Ville Tikka, Vahid Vahidinasab, et al.. (2025). Vehicle-to-everything (V2X): an updated review of key research challenges, implementation barriers, and real-world innovation projects. IET conference proceedings.. 2024(5). 748–758.

Belotti, Angelo, Barbara Frittoli, Rossella Ribolla, et al.. (2024). Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score. Blood. 144(Supplement 1). 82–82. 1 indexed citations

Belotti, Angelo, Rossella Ribolla, Claudia Crippa, et al.. (2023). Predictive role of sustained imaging MRD negativity assessed by diffusion‐weighted whole‐body MRI in multiple myeloma. American Journal of Hematology. 98(9). E230–E232. 5 indexed citations

Belotti, Angelo, Rossella Ribolla, Claudia Crippa, et al.. (2022). Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy. Blood. 140(Supplement 1). 1140–1141. 2 indexed citations

Montefusco, Vittorio, Alessandro Corso, Mónica Galli, et al.. (2020). Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. British Journal of Haematology. 188(6). 907–917. 7 indexed citations

Borlenghi, Erika, Chiara Cattaneo, Elisa Cerqui, et al.. (2020). Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long‐term outcome in European leukemia net favorable and intermediate‐risk acute myeloid leukemia. Hematological Oncology. 38(5). 754–762. 8 indexed citations

Montefusco, Vittorio, Alessandro Corso, Mónica Galli, et al.. (2017). Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study. Blood. 130(Suppl_1). 836–836. 2 indexed citations

Gambella, Manuela, Alberto Rocci, Roberto Passera, et al.. (2014). High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica. 99(2). e14–e16. 47 indexed citations

10.

Larocca, Alessandra, Vittorio Montefusco, Sara Bringhen, et al.. (2013). Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 122(16). 2799–2806. 66 indexed citations

11.

Corso, Alessandro, Mónica Galli, Silvia Mangiacavalli, et al.. (2011). Response‐adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression‐free survival in transplanted patients with multiple myeloma. American Journal of Hematology. 87(2). 150–154. 8 indexed citations

12.

Spina, Francesco, Vittorio Montefusco, Claudia Crippa, et al.. (2011). Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. Leukemia & lymphoma. 52(7). 1262–1270. 9 indexed citations

13.

Ladetto, Marco, G Pagliano, Simone Ferrero, et al.. (2010). Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma. Journal of Clinical Oncology. 28(12). 2077–2084. 181 indexed citations

14.

Palumbo, Antonio, Francesca Gay, Patrizia Falco, et al.. (2010). Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. Journal of Clinical Oncology. 28(5). 800–807. 114 indexed citations

15.

Galli, Mónica, Silvia Salmoiraghi, Josée Golay, et al.. (2009). A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Annals of Hematology. 89(2). 185–190. 92 indexed citations

16.

Crippa, Claudia, et al.. (2009). Fire risk management system for safe operation of large atmospheric storage tanks. Journal of Loss Prevention in the Process Industries. 22(5). 574–581. 11 indexed citations

17.

Gay, Francesca, Patrizia Falco, Claudia Crippa, et al.. (2009). Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.. Blood. 114(22). 3419–3419. 1 indexed citations

18.

Re, Alessandro, Silvia Ferrari, Paolo Frata, et al.. (2008). Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. Annals of Oncology. 19(5). 951–957. 2 indexed citations

19.

Palumbo, Antonio, Patrizia Falco, Francesca Gay, et al.. (2008). Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results. Blood. 112(11). 2768–2768. 3 indexed citations

20.

Todeschini, Giuseppe, Cristina Tecchio, Felice Pasini, et al.. (2005). Hyperfractionated cyclophosphamide with high‐doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897). Cancer. 104(3). 555–560. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact